NCT06710197 2026-03-05
OZM-034
University Health Network, Toronto
Phase 2 Withdrawn
Clinical Trials
8 trialsNCT04205838 2026-02-27
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT02021422 2026-02-18
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
Baylor Research Institute
Phase 1 Completed
NCT05013450 2025-12-17
Dupilumab_Metastatic NSCLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Active not recruiting
NCT04150913 2025-11-25
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Massachusetts General Hospital
Phase 2 Completed
NCT04148430 2025-11-05
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04359784 2025-10-23
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT06703216 2025-06-15
PACER
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1/2 Not yet recruiting